Latest Lead News

Integral Diagnostics Limited (ASX – IDX) reported a robust FY25 performance, boosted by its transformative merger with Capitol Health Limited. The company posted strong revenue and profit growth, declared a 4.0 cent final dividend, and outlined strategic priorities including AI adoption and teleradiology expansion.

Rhythm Biosciences has completed critical validation of its ColoSTAT colorectal cancer assay and submitted it for ISO15189 accreditation, paving the way for commercialisation. The test demonstrated strong clinical performance, highlighting its potential as a non-invasive diagnostic tool.

Tribeca Global Natural Resources Limited (ASX – TGF) has declared a fully franked 5-cent dividend for FY25 alongside a 10% on-market buyback, while delivering returns that outpaced major natural resource indices. The company’s portfolio is well positioned to benefit from rising strategic demand for critical and precious metals amid evolving global market dynamics.

Imugene Limited reported a significant 54% reduction in net loss for FY25, driven by cost efficiencies and promising clinical progress in its immuno-oncology pipeline. The company’s lead asset, azer-cel, achieved a 79% response rate in Phase 1b trials and secured FDA Fast Track designation.

Kip McGrath Education Centres Limited reported modest revenue growth and a solid increase in EBITDA for FY25, despite a significant net loss driven by its exit from the US market. The company declared a fully franked final dividend, signaling confidence in its refocused core business.

EMVision Medical Devices is set to activate its sixth and final pivotal trial site at UCLA Health, advancing its emu™ brain scanner towards FDA submission. Meanwhile, the Continuous Innovation Study grows with the addition of Box Hill Hospital.

Amplia Therapeutics has successfully raised A$2.65 million through its Share Purchase Plan, exceeding expectations and bolstering funding for pivotal clinical trials of its lead drug narmafotinib.

Propel Funeral Partners has reported record FY25 results, exceeding revenue and EBITDA guidance while maintaining steady dividends and announcing a key executive transition.

Chrysos Corporation reported a robust 46% revenue increase to A$66.1 million for FY25 but faced a significant net loss of A$8.2 million, reflecting rising costs and operational challenges.

IperionX secures a $12.5 million funding tranche from the U.S. Department of Defense to fast-track expansion of its Virginia titanium manufacturing capacity beyond 1,000 metric tons annually.

Big River Industries reported a 2.3% revenue decline for FY25 amid tough market conditions but achieved a notable rebound in the second half, driven by operational efficiencies and cost controls. The company maintains a strong balance sheet and a cautiously optimistic outlook for FY26.

Big River Industries reported a modest revenue decline in FY25 but achieved improved margins and operational efficiencies in the second half, positioning itself for growth as market conditions begin to stabilise.